IND Swift Laboratories Ltd

Ind-Swift Laboratories Ltd. will hold a board meeting on Thursday, October 29, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ind-Swift Laboratories Limited announced that its Preferential Issue Committee has approved the allotment of 14,00,000 equity shares with a face value of Rs 10 each to Essix Biosciences Limited, a promoter group entity, upon the conversion of an equal number of fully convertible warrants. The conversion involved a consideration of Rs 147 per warrant, totaling Rs 20,58,00,000, and was executed at an issue price of Rs 196 per warrant. Consequently, the company's paid-up equity share capital increased from Rs 86,71,15,580 comprising 8,67,11,558 equity shares to Rs 86,96,15,580 comprising 8,69,61,558 equity shares.

Ind-Swift Laboratories Limited submitted a certificate to the Bombay Stock Exchange and National Stock Exchange of India confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as received from Alankit Assignments Limited, the company's Registrar and Share Transfer Agent.

Ind-Swift Laboratories Ltd. will close its trading window for promoters, members of the promoter group, directors, key managerial personnel, designated persons, connected persons/insiders and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, in compliance with securities regulations and the company’s code of fair disclosure.

Ind-Swift Laboratories Limited announced that its Preferential Issue Committee approved the allotment of 70,00,000 fully convertible warrants at a price of Rs 196 per warrant, including a premium of Rs 186, to Essix Biosciences Limited, an entity belonging to the ‘Promoter & Promoter Group,’ for a total subscription price of Rs 34,30,00,000.

IND-SWIFT LABORATORIES LTD. announced the appointment of Mr. Amit Mathur as an Additional Director, in the category of Non-Executive Independent Director, effective September 3, 2026, for a period of five years subject to member approval at the company’s 31st Annual General Meeting, scheduled for September 30, 2026. The company also announced the reconstitution of its Audit Committee, effective September 3, 2026, and appointed Care Ratings Limited as the Monitoring Agency for the utilization of proceeds from a preferential issue approved on August 5, 2026.

Shekhawati Industries Ltd, Kolte Patil Developers Ltd, Bhartiya International Ltd and Godavari Biorefineries Ltd are among the other gainers in the BSE's 'B' group today, 11 August 2026.Ind-Swift Laboratories Ltd spiked 19.99% to Rs 284.5 at 12:03 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 3.18 lakh shares were traded on the counter so far as against the average daily volumes of 27509 shares in the past one month. Shekhawati Industries Ltd soared 19.94% to Rs 16.24. The stock was the second biggest gainer in 'B' group. On the BSE, 23433 shares were traded on the counter so far as against the average daily volumes of 8536 shares in the past one month. Kolte Patil Developers Ltd surged 17.53% to Rs 545.2. The stock was the third biggest gainer in 'B' group. On the BSE, 4.39 lakh shares were traded on the counter so far as against the average daily volumes of 11601 shares in the past one month. Bhartiya International Ltd rose 17.13% to Rs 965. The stock was the fourth biggest gainer in 'B' group. On the BSE, 102 shares were traded on the counter so far as against the average daily volumes of 518 shares in the past one month. Godavari Biorefineries Ltd jumped 14.74% to Rs 275.6. The stock was the fifth biggest gainer in 'B' group. On the BSE, 2.01 lakh shares were traded on the counter so far as against the average daily volumes of 10020 shares in the past one month.

Ind-Swift Laboratories Limited informed the BSE Limited and National Stock Exchange of India that there was no deviation or variation in the use of funds raised through a preferential issue of convertible warrants, according to a statement reviewed by the company's Audit Committee for the quarter ended June 30, 2026. The company received Rs 255.61 crore out of a total issue size of Rs 314.60 crore on August 30, 2024, and noted that Rs 58.99 crore became non-receivable from Saral Incorporated VCC Sub Fund 1 due to the warrants' tenure expiring and the allottee failing to convert them into equity.

IND-SWIFT LABORATORIES LTD. announced that shareholders approved amendments to the company’s Articles of Association through an Extra-Ordinary General Meeting on August 5, 2026, via e-voting, specifically addressing the retirement of directors by rotation and re-appointment eligibility in accordance with Section 152 of the Companies Act, 2013 and applicable regulations.

Ind-Swift Laboratories Limited held its 1st Extra Ordinary General Meeting (EGM) for the financial year 2026-27 on Wednesday, August 5th, 2026, via video conferencing, according to a corporate disclosure. The meeting, chaired by Sh. Navrattan Munjal, commenced at 11:30 A.M. IST and concluded at 12:01 P.M. IST, with 52 shareholders participating, and resolutions including the issuance of up to 70,00,000 fully convertible warrants and the re-appointment of Sh. Rajinder Kumar Gupta as an independent director, approved via remote e-voting and e-voting during the EGM.